OPL (Oxigen polyatomic liquid) technology was invented by Professor Giovanni Barco in 1996 and is an oxidative therapy. It received its pharmacological basis from the action of molecular oxygen species, providing homeostatic regulation of cellular oxidation-reduction reactions, the production of radicals in order to modulate mitochondrial pathways that produce cellular energy.

The therapy returns to the physiological level vital energy reactions in cells, which are reduced to a minimum or occur with abnormalities under conditions of illness or aging.

OPL (Oxigen polyatomic liquid) is the main component of oxidative therapy, which is based on the intravenous administration of free radicals in an aqueous solution of superoxide paramagnetic anion (O2-). OPL can reach areas of tissue that are not normally washed by arterial blood, activating mitochondrial oxidative systems, usually involved in energy production, which are significantly slowed down in special pathological conditions or with simple aging. Oxygen used in OPL has a triplet state 3О2 (3Σg-) - singlet oxygen.


A device for the generation and injection of medical allotropic fluids TOTEM OPL 0812/1958 has been developed and patented, which has a CE certificate and ISO 9001.

Protocols for treating patients with various diseases (including oncological diseases and COVID-19) have been developed and approved.

Melianta Limited is ready to lease the above equipment, supply components for injections, train the partner's personnel with the participation of specialists from the International Barco Institute, and provide online access to the current treatment protocols developed by the Institute.

Melianta Limited undertakes to ensure systematic access of the equipment to the servers of the Institute for the treatment of patients using OPL technology, to carry out warranty and service maintenance of the equipment and quality control.